Carmel Diagnostics (כרמל דיאגנוסטיקה)

Kiryat Tiv'on, New York, United States

Diagnostics Precision Medicine/Diagnostics

Carmel Diagnostics has developed a method for measuring the oxidative stress (OS) of biological liquids, a recognized biomarker of health and disease and a key diagnostics parameter. This OS parameter is measured using thermochemiluminescence (TCL) technology. The company's lead product is focused on the process of embryo selection in in-vitro fertilization (IVF). The Fertissimo TCL Analyzer is a noninvasive embryo selection system for the IVF market, offering up to a 20% increase in successful IVF pregnancies. Effective embryo viability assessment significantly improves the success rate and reduces the risk of multiple births. Carmel Diagnostics has performed two successful proof-of-concept studies covered by peer-reviewed articles on the applications of risk stratification for patients with congestive heart failure and embryo selection in the IVF process, and is currently performing a clinical validation study for the IVF application. Carmel Diagnostics was awarded a Horizon 2020 phase-2 grant.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Carmel Diagnostics (כרמל דיאגנוסטיקה) on @MedStartr Today #DiseaseManagement #EarlyDiseaseDetection #GeneralHealth #Diagnostics #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/GpStxTypnYw

Get Involved in Carmel Diagnostics (כרמל דיאגנוסטיקה)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2009
Website: www.carmel-diagnostics.com/

Disease Areas

Disease Management Early Disease Detection General Health

Technologies

BiomarkersDiagnostic TestingLaboratory TechnologyAnalytical Instrumentation

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Carmel Diagnostics (כרמל דיאגנוסטיקה)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.